GLSI vs. PBYI, ETTX, MITO, ALXO, CALT, DNTH, SLN, ANAB, AVBP, and HROW
Should you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Puma Biotechnology (PBYI), Entasis Therapeutics (ETTX), Stealth BioTherapeutics (MITO), ALX Oncology (ALXO), Calliditas Therapeutics AB (publ) (CALT), Dianthus Therapeutics (DNTH), Silence Therapeutics (SLN), AnaptysBio (ANAB), ArriVent BioPharma (AVBP), and Harrow (HROW). These companies are all part of the "medical" sector.
Greenwich LifeSciences (NASDAQ:GLSI) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, community ranking, risk, valuation, dividends, earnings and analyst recommendations.
4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 52.9% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 23.7% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Puma Biotechnology has a net margin of 6.79% compared to Greenwich LifeSciences' net margin of 0.00%. Puma Biotechnology's return on equity of 35.49% beat Greenwich LifeSciences' return on equity.
In the previous week, Greenwich LifeSciences had 12 more articles in the media than Puma Biotechnology. MarketBeat recorded 17 mentions for Greenwich LifeSciences and 5 mentions for Puma Biotechnology. Greenwich LifeSciences' average media sentiment score of 1.08 beat Puma Biotechnology's score of 0.68 indicating that Greenwich LifeSciences is being referred to more favorably in the media.
Puma Biotechnology has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
Puma Biotechnology received 531 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 66.54% of users gave Puma Biotechnology an outperform vote while only 37.50% of users gave Greenwich LifeSciences an outperform vote.
Greenwich LifeSciences currently has a consensus target price of $36.00, indicating a potential upside of 172.93%. Puma Biotechnology has a consensus target price of $7.00, indicating a potential upside of 74.13%. Given Greenwich LifeSciences' higher probable upside, analysts plainly believe Greenwich LifeSciences is more favorable than Puma Biotechnology.
Greenwich LifeSciences has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.
Summary
Puma Biotechnology beats Greenwich LifeSciences on 10 of the 15 factors compared between the two stocks.
Get Greenwich LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Greenwich LifeSciences Competitors List
Related Companies and Tools
